共 39 条
Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and β-secretase inhibition activities
被引:28
作者:
Ghobadian, Roshanak
[1
]
Mahdavi, Mohammad
[2
]
Nadri, Hamid
[3
,4
]
Moradi, Alireza
[3
,4
]
Edraki, Najmeh
[5
]
Akbarzadeh, Tahmineh
[1
,6
]
Sharifzadeh, Mohammad
[7
]
Bukhari, Syed Nasir Abbas
[8
]
Amini, Mohsen
[1
]
机构:
[1] Univ Tehran Med Sci, Dept Med Chem, Fac Pharm, Tehran 14176, Iran
[2] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Endocrinol & Metab Clin Sci Inst, Tehran, Iran
[3] Shahid Sadoughi Univ Med Sci, Pharmaceut Sci Res Ctr, Yazd 8915173143, Iran
[4] Shahid Sadoughi Univ Med Sci, Fac Pharm, Yazd 8915173143, Iran
[5] Shiraz Univ Med Sci, Med & Nat Prod Chem Res Ctr, Shiraz, Iran
[6] Univ Tehran Med Sci, Persian Med & Pharm Res Ctr, Tehran, Iran
[7] Univ Tehran Med Sci, Dept Pharmacol & Toxicol, Fac Pharm, Tehran, Iran
[8] Jouf Univ, Dept Pharmaceut Chem, Coll Pharm, Al Jouf 2014, Sakaka, Saudi Arabia
关键词:
Alzheimer's disease;
Butyrylcholinesterase;
Docking study;
2,3,4,9-Tetrahydro-1H-carbazole;
In-vitro assay;
SITE ACETYLCHOLINESTERASE INHIBITORS;
ALZHEIMERS-DISEASE;
BIOLOGICAL EVALUATION;
BUTYRYLCHOLINESTERASE INHIBITORS;
DRUG CANDIDATES;
IN-VITRO;
DERIVATIVES;
DESIGN;
MOIETY;
DOCKING;
D O I:
10.1016/j.ejmech.2018.05.031
中图分类号:
R914 [药物化学];
学科分类号:
100705 [微生物与生化药学];
摘要:
Butyrylcholinesterase (BuChE) inhibitors have become interesting target for treatment of Alzheimer's disease (AD). A series of dual binding site BuChE inhibitors were designed and synthesized based on 2,3,4,9-tetrahydro-1H-carbazole attached benzyl pyridine moieties. In-vitro assay revealed that all of the designed compounds were selective and potent BuChE inhibitors. The most potent BuChE inhibitor was compound 6i (IC50 = 0.088 +/- 0.0009 mu M) with the mixed-type inhibition. Docking study revealed that 6i is a dual binding site BuChE inhibitor. Also, Pharmacokinetic properties for 6i were accurate to Lipinski's rule. In addition, compound 6i demonstrated neuroprotective and beta-secretase (BACE1) inhibition activities. This compound could also inhibit AChE-induced and self-induced A beta peptide aggregation at concentration of 100 mu M and 10 mu M respectively. Generally, the results are presented as new potent selective BuChE inhibitors with a therapeutic potential for the treatment of AD. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:49 / 60
页数:12
相关论文

